Tarrytown, NY, United States of America

Meagan P O'BRIEN

This inventor holds 2 USPTO granted patents. Top assignees: Regeneron Pharmaceuticals, Inc., Sanofi Biotechnology. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Meagan P O'BRIEN. Retrieved from https://idiyas.com/inventor/meagan-p-o-brien-lpf7rawq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Meagan P O'Brien: Innovator in Allergy Treatment

Introduction

Meagan P O'Brien is a notable inventor based in Tarrytown, NY (US). She has made significant contributions to the field of allergy treatment through her innovative research and development. Her work is particularly focused on the use of antibodies to address allergic reactions.

Latest Patents

Meagan holds a patent for "Methods of Treating Allergy Using Anti-Bet V 1 Antibodies." This patent represents her commitment to advancing medical treatments and improving the quality of life for individuals suffering from allergies.

Career Highlights

Meagan is currently employed at Regeneron Pharmaceuticals, Inc., where she continues to work on groundbreaking research in the field of immunology. Her role at Regeneron allows her to collaborate with other experts and contribute to the development of innovative therapies.

Collaborations

Due to space constraints, the details of her collaborations will not be included.

Conclusion

Meagan P O'Brien is a pioneering inventor whose work in allergy treatment exemplifies the impact of innovation in healthcare. Her contributions are vital in the ongoing quest to improve therapeutic options for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…